Skip to main content

Table 3 Results of sensitivity analysis

From: Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma

Outcome

No. of studies

No.of patients

Results

OR (95% CI)

P value

HG p value

TACE (+)

TACE (−)

TACE (+)

TACE (−)

RCTs

        

5-years disease-free survival

4[14–16, 24]

167

172

29.3%

31.9%

0.85 (0.53, 1.39)

0.52

0.16

5-years overall survival

4[14–16, 24]

167

172

36.5%

38.3%

0.89 (0.56, 1.41)

0.61

0.11

Total recurrence

3[14, 16, 24]

116

124

74.1%

74.2%

1.03 (0.36, 2.90)

0.96

0.07

Intrahepatic recurrence

3[14, 16, 24]

116

124

50.0%

46.7%

1.32 (0.47, 3.70)

0.59

0.02

Extrahepatic recurrence

3[14, 16, 24]

116

124

28.4%

22.5%

1.37 (0.42, 4.43)

0.60

0.04

Overall morbidity

3[14, 16, 24]

113

127

20.3%

21.2%

0.97 (0.52, 1.82)

0.93

0.14

Mortality

4[14–16, 24]

163

174

3.1%

4.0%

0.70 (0.22, 2.30)

0.56

0.95

NRCTs

        

5-years disease-free survival

14[10, 11, 13, 28, 31–40]

1108

1395

32.4%

29.8%

1.28 (0.98, 1.67)

0.07

0.04

5-years overall survival

12[11, 12, 28, 29, 31, 34–40]

871

1291

40.9%

46.1%

0.86 (0.55, 1.32)

0.48

<0.01

Total recurrence

8[10, 30, 32, 35, 36, 38–40]

559

795

58.1%

55.8%

0.98 (0.77, 1.25)

0.86

0.11

Intrahepatic recurrence

9[10–12, 29, 30, 32, 35, 36, 39]

546

675

51.2%

56.5%

0.79 (0.62, 1.01)

0.06

0.84

Extrahepatic recurrence

6[10, 30, 32, 35, 36, 39]

403

467

8.4%

7.0%

1.22 (0.73, 2.06)

0.44

0.74

Overall morbidity

8[10–12, 29, 30, 35, 36, 40]

470

676

31.0%

27.9%

1.03 (0.79, 1.36)

0.81

0.50

Mortality

12[10–12, 28–30, 33–36, 38, 40]

937

1151

4.3%

2.9%

1.39 (0.85, 2.28)

0.19

0.74

Studies with complete matched clinicopathological parameters

        

5-years disease-free survival

6[15, 16, 28, 32, 35, 39]

421

404

26.8%

22.0%

1.13 (0.62, 2.05)

0.69

0.02

5-years overall survival

7[12, 15, 16, 28, 32, 35, 39]

452

511

44.6%

35.2%

1.15 (0.76, 1.74)

0.50

0.08

Total recurrence

5[16, 30, 32, 35, 39]

297

349

73.7%

76.5%

0.91 (0.62, 1.33)

0.64

0.15

Intrahepatic recurrence

6[12, 16, 30, 32, 35, 39]

328

456

56.4%

60.1%

0.81 (0.59, 1.11)

0.20

0.69

Extrahepatic recurrence

5[16, 30, 32, 35, 39]

297

349

13.1%

9.4%

1.40 (0.83, 2.38)

0.21

0.80

Overall morbidity

4[12, 16, 30, 35]

191

344

36.1%

28.2%

1.36 (0.91, 2.01)

0.13

0.48

Mortality

6[12, 15, 16, 28, 30, 35]

339

423

4.4%

3.7%

1.16 (0.52, 2.57)

0.71

0.50

  1. HG heterogeneity.